In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack
A peer-reviewed publication has given backing to a cancer immunotherapy platform developed by () – one of ’s () portfolio companies.
The article, published online earlier this month in the Journal of Immunology, describes how the Versamune platform recruits and activates T-cells.
T-cells are responsible for identifying and attacking cancer cells while at the same time making them more susceptible to T-cell attack.
A phase II study of PDS0101 – the lead drug from the Versamune platform – in combination with Merck’s Keytruda in head and neck cancer patients is due to kick off later this year.
Similar studies testing PDS0101 in advanced HPV-associated cancers and on its own in cervical dysplasia are also planned.
Shares in Netscientific, which owns 8.15% of PDS’s stock, rose 16.5% to 9.03p in late-afternoon trading on Thursday.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE